Filtered By:
Condition: Polyps
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 2492 results found since Jan 2013.
Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS ‐24 and SINUS‐52
ConclusionMost patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of IL-4 and IL-13 signaling, key and central drivers of type 2 inflammation in CRSwNP.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - August 7, 2023 Category: Allergy & Immunology Authors: Claus Bachert,
Asif H. Khan,
Stella E. Lee,
Claire Hopkins,
Anju T. Peters,
Wytske Fokkens,
Amy Praestgaard,
Amr Radwan,
Scott Nash,
Juby A. Jacob ‐Nara,
Yamo Deniz,
Paul J. Rowe Tags: ORIGINAL ARTICLE Source Type: research
Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)
ConclusionIn CRSwNP patients, combined ESS and biologic therapy results in a significant and sustained decrease in polyp burden compared to biologic therapy alone. Larger studies are warranted to further examine the impact of combined therapy.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - July 28, 2023 Category: Allergy & Immunology Authors: Emily Garvey,
Bita Naimi,
Alexander Duffy,
Paavali Hannikainen,
Chase Kahn,
Douglas Farquhar,
Marc Rosen,
Mindy Rabinowitz,
Elina Toskala,
Gurston Nyquist Tags: ORIGINAL ARTICLE Source Type: research
Systematic Review of Protein Biomarkers in Adult Patients With Chronic Rhinosinusitis
CONCLUSION: We have identified numerous potential biomarkers to differentiate a range of CRS phenotypes. Future studies should focus on the prognostic role of nasal tissue biomarkers or expand on the more limited studies of nasal secretions and nasal lavage fluid.We registered this study in PROSPERO (CRD42022302787).PMID:37491901 | DOI:10.1177/19458924231190568
Source: American Journal of Rhinology and Allergy - July 26, 2023 Category: ENT & OMF Authors: Shyam A Gokani Andreas Espehana Ana C Pratas Louis Luke Ekta Sharma Jennifer Mattock Jelena Gavrilovic Allan Clark Tom Wileman Carl M Philpott Source Type: research
miR ‐200a‐3p regulates epithelial–mesenchymal transition and inflammation in chronic rhinosinusitis with nasal polyps by targeting ZEB1 via ERK/p38 pathway
ConclusionsmiR-200a-3p suppresses EMT and inflammation by regulating the expression of ZEB1 via the ERK/p38 pathway. Our study presents new ideas for protecting nasal epithelial cells from tissue remodeling and finding a possible target for disease.
Source: International Forum of Allergy and Rhinology - July 20, 2023 Category: Allergy & Immunology Authors: Yisha Wu,
Kaiyue Sun,
Yanyi Tu,
Ping Li,
Dingqian Hao,
Peng Yu,
Aiping Chen,
Yuzhu Wan,
Li Shi Tags: ORIGINAL ARTICLE Source Type: research
Real ‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: impact of comorbidity and sinus surgery
ConclusionsConsistent with trial data, mepolizumab use in real-world practice shows benefits across comorbid patient cohorts with more a pronounced impact in those with severe asthma+comorbid CRS + sinus surgery.
Source: International Forum of Allergy and Rhinology - July 20, 2023 Category: Allergy & Immunology Authors: Jared Silver,
Arijita Deb,
Fran çois Laliberté,
Chi Gao,
Neil Bhattacharyya Tags: ORIGINAL ARTICLE Source Type: research
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents ’ efficacy
ConclusionsAlthough the present analysis showed a moderate supremacy of dupilumab, there is still no evidence-based answer to the question “which biologic agent is the most effective in CRS treatment?” Improved statistical methodology, head-to-head trials, and real-life studies could lead to more robust conclusions, establishing the real role of the specific biologic agents.
Source: International Forum of Allergy and Rhinology - July 19, 2023 Category: Allergy & Immunology Authors: Georgios X. Papacharalampous,
Jannis Constantinidis,
George Fotiadis,
Nan Zhang,
Claus Bachert,
Michael Katotomichelakis Tags: REVIEW ARTICLE Source Type: research
Crocin Inhibits the Type 2 Inflammatory Response Produced by ILC2s in Eosinophilic Nasal Polyps
CONCLUSION: Crocin inhibited type 2 inflammation induced by ILC2 activation at low concentrations via inhibiting the activation of NF-κB.PMID:37424236 | DOI:10.1177/19458924231185296
Source: American Journal of Rhinology and Allergy - July 10, 2023 Category: ENT & OMF Authors: Xu Xiaodong Li Tao Liu Jianmin Zhou Jing Zhong Bing Du Jintao Claus Bachert Ba Luo Source Type: research
